✦ LIBER ✦

Combination Therapy of Colon Carcinoma 26 in Mice with Recombinant Human Interleukin-2 and Interferon-α A/D: Occurrence of Large Granular Cells in the Tumor

✍ Scribed by Sakura, Yasufumi ;Ootsu, Koichiro ;Shino, Akio

Book ID: 108578876
Publisher: Wiley (Blackwell Publishing)
Year: 1989
Tongue: English
Weight: 996 KB
Volume: 80
Category: Article
ISSN: 0910-5050
DOI: 10.1111/j.1349-7006.1989.tb01732.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Antitumor Effect of Recombinant Human In

Antitumor Effect of Recombinant Human Interleukin-2 on the Growth of Murine Hemangioendothelioma D14 in Nude Mice: Occurrence of Large Granular Cells in the Tumor

✍ Sakura, Yasufumi ;Houkan, Takashi ;Ootsu, Koichiro ;Shino, Akio 📂 Article 📅 1991 🏛 Wiley (Blackwell Publishing) 🌐 English ⚖ 875 KB

Inhibitory Effects of Interleukin-4 on H

Inhibitory Effects of Interleukin-4 on Human Renal Cell Carcinoma Cells In Vitro: In Combination with Interferon-α, Tumor Necrosis Factor-α or Interleukin-2

✍ Jun Cheon; Dong Joon Chung; Je Jong Kim; Sung Kun Koh; Jeongwon Sohn 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 747 KB

Antitumor effects of the combination the

Antitumor effects of the combination therapy with TNF-α gene–modified tumor cells and interleukin 12 in a melanoma model in mice

✍ Lasek, Witold; Mackiewicz, Andrzej; Czajka, Anna; Świtaj, Tomasz; Gołąb, Jakub; 📂 Article 📅 2000 🏛 Nature Publishing Group 🌐 English ⚖ 222 KB

Recombinant interferon α-2A combined wit

Recombinant interferon α-2A combined with prednisone in metastatic renal-cell carcinoma: Treatment results, serum interferon levels and the development of antibodies

✍ Sophie D. Fosså; Gustav Lehne; Ragnhild Gunderson; Unni Hielmaas; Eduard E. Hold 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 French ⚖ 375 KB 👁 1 views

Five partial responses were seen in 23 patients with metastatic renal-cell carcinoma (MRCC) receiving interferon-a 2a (IFN) + prednisone (P). Four of 24 subsequent patients responded to IFN + P (combined response rate 19%). The median response duration was 8 months (3 to 30 months). The one-year sur

Subcutaneous interleukin-2 and interfero

Subcutaneous interleukin-2 and interferon α in the treatment of patients with metastatic renal cell carcinoma—Less efficacy compared with intravenous interleukin-2 and interferon α : Results of a multicenter Phase II trial from the Groupe Français d'Immunothérapie

✍ Alain Ravaud; Rémy Delva; Fréderic Gomez; Christine Chevreau; Jean-Yves Douillar 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB 👁 1 views

## Background: The main objective of this trial was to evaluate the combination of subcutaneous (sc) interleukin-2 (il-2) with interferon alpha-2a (ifn-alpha) in the treatment of patients with metastatic renal cell carcinoma (mrcc) compared with a previous trial that used continuous-infusion il-2 a